Drugs / Emfilermin
Emfilermin
also known as
r-hLIF · recombinant human leukemia inhibitory factor · AM-424 · Emfilermina · Emfilermine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00504608 | Apr 2003 → Apr 2004 | low implantation of placenta | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1/2 | NCT00504530 | Sep 2001 → Apr 2002 | — | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Emfilermin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00504530 ↗ |
| Known as | AM-424 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108400 ↗ |
| Known as | Emfilermina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108400 ↗ |
| Known as | Emfilermine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108400 ↗ |
| Known as | r-hLIF | “Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)” NCT00504608 ↗1“Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)” NCT00504530 ↗ |
| Known as | recombinant human leukemia inhibitory factor | “Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)” NCT00504608 ↗1“Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)” NCT00504530 ↗ |
| Modality | Protein / enzyme biologic | “Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)” NCT00504530 ↗ |